MA
VRTX icon

Montag & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Montag & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$423K Buy
852
+35
+4% +$15.5K 0.02% 338
2026
Q1 		$365K Buy
817
+20
+3% +$9.33K 0.02% 343
2025
Q4 		$361K Buy
797
+587
+280% +$253K 0.02% 336
2025
Q3 		$82.2K Sell
210
-300
-59% -$125K ﹤0.01% 515
2025
Q2 		$227K Buy
510
+25
+5% +$11.5K 0.01% 383
2025
Q1 		$235K Hold
485
– – 0.01% 398
2024
Q4 		$195K Sell
485
-462
-49% -$214K 0.01% 427
2024
Q3 		$440K Buy
947
+39
+4% +$18.7K 0.02% 337
2024
Q2 		$426K Buy
908
+473
+109% +$205K 0.02% 328
2024
Q1 		$182K Buy
435
+50
+13% +$21.1K 0.01% 424
2023
Q4 		$157K Buy
385
+200
+108% +$73.9K 0.01% 426
2023
Q3 		$64.3K Hold
185
– – ﹤0.01% 511
2023
Q2 		$65.1K Sell
185
-3
-2% -$1.01K ﹤0.01% 519
2023
Q1 		$59.2K Hold
188
– – ﹤0.01% 526
2022
Q4 		$54.3K Buy
188
+19
+11% +$5.79K ﹤0.01% 528
2022
Q3 		$49K Hold
169
– – ﹤0.01% 538
2022
Q2 		$48K Hold
169
– – ﹤0.01% 535
2022
Q1 		$44K Hold
169
– – ﹤0.01% 589
2021
Q4 		$37K Hold
169
– – ﹤0.01% 611
2021
Q3 		$31K Hold
169
– – ﹤0.01% 631
2021
Q2 		$34K Hold
169
– – ﹤0.01% 598
2021
Q1 		$36K Hold
169
– – ﹤0.01% 594
2020
Q4 		$40K Buy
+169
New +$38.8K ﹤0.01% 564

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Montag & Associates's VRTX Position: Q2 2026 in Review

Montag & Associates increased its Vertex Pharmaceuticals (VRTX) stake by 4.3% in Q2 2026, buying an estimated $15.5K and bringing the position to 852 shares worth $423K. The position accounts for 0.02% of the portfolio, ranked #338.

Montag & Associates first reported a position in VRTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $440K in Q3 2024. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Montag & Associates held 852 shares of Vertex Pharmaceuticals worth $423K as of Q2 2026.
  • Montag & Associates bought 35 Vertex Pharmaceuticals shares in Q2 2026, an estimated $15.5K.
  • Vertex Pharmaceuticals made up 0.02% of Montag & Associates's portfolio in Q2 2026, its #338 holding.
  • Montag & Associates first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 23 quarters since.
  • Montag & Associates's Vertex Pharmaceuticals position peaked at $440K in Q3 2024.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Montag & Associates's 13F filing for Q2 2026, filed 5 Aug 2026.